{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:14:50Z","timestamp":1793661290923,"version":"4.5.1"},"reference-count":320,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Carbapenems comprise a class of \u03b2-lactam antibiotics with broad-spectrum hydrolytic activity and are often reserved as last-line agents for the treatment of serious multidrug-resistant (MDR) bacterial infections. Clinically important nosocomial MDR Gram-negative bacteria (GNB) include Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Carbapenem resistance among these organisms is predominantly mediated by the production of \u03b2-lactamases called carbapenemases, such as K. pneumoniae carbapenemase (KPC), New Delhi metallo-\u03b2-lactamase (NDM), imipenemase (IMP), Verona integron-encoded metallo-\u03b2-lactamase (VIM), and selected oxacillinase (OXA)-type carbapenemases. These enzymes degrade carbapenems, significantly compromising their clinical efficacy. To address escalating antimicrobial resistance, novel next-generation \u03b2-lactamase inhibitors (BLIs), partnered with established \u03b2-lactams (BLs), have been approved or are currently under development to inhibit carbapenemase activity. The present narrative review aims to synthesize the most current information on the major carbapenemases and discusses recently approved and investigational BL\/BLI combination therapies in terms of their mechanisms of action, spectrum of activity, gaps in coverage, and available clinical and in vitro evidence. Development of resistance to novel BL\/BLI combinations is also examined. Comparative analysis of inhibitory spectra and microbiological coverage indicates a continued need for metallo-\u03b2-lactamase inhibitors with direct pan-inhibitory activity, pathogen-specific BL\/BLI regimens for carbapenem-resistant A. baumannii, and carbapenemase-targeted agents effective in the context of non-enzymatic resistance mechanisms. Treatment-emergent resistance to novel BL\/BLIs and limitations in activity profiles underscore the critical need for continued innovation in pipeline development, vigilant global and local surveillance of carbapenemase epidemiology, and robust antimicrobial stewardship strategies to aid in preserving the efficacy of the antibacterial drug armamentarium.<\/jats:p>","DOI":"10.3390\/antibiotics15040413","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:37:42Z","timestamp":1776677862000},"page":"413","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in \u03b2-Lactamase Inhibitor Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Jessi M.","family":"Grossman","sequence":"first","affiliation":[{"name":"South College School of Pharmacy, Knoxville, TN 37922, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6017-8359","authenticated-orcid":false,"given":"Dorothea K.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, South College School of Pharmacy, Knoxville, TN 37922, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: A prioritization study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: Past, present, and future","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/24.suppl_A.1","article-title":"The carbapenems: New broad spectrum beta-lactam antibiotics","volume":"24","author":"Moellering","year":"1989","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0924-8579(98)00094-6","article-title":"Carbapenems in clinical practice: A guide to their use in serious infection","volume":"11","author":"Bradley","year":"1999","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1469-0691.2000.00107.x","article-title":"Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs)","volume":"6","author":"Paterson","year":"2000","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: A clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cll.2017.01.005","article-title":"Carbapenem-Resistant Enterobacteriaceae","volume":"37","author":"Iovleva","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s10096-021-04296-1","article-title":"Treatment for carbapenem-resistant Enterobacterales infections: Recent advances and future directions","volume":"40","author":"Tompkins","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40121-020-00395-2","article-title":"Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria","volume":"10","author":"Hansen","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molmed.2012.03.003","article-title":"Carbapenem resistance in Enterobacteriaceae: Here is the storm!","volume":"18","author":"Nordmann","year":"2012","journal-title":"Trends Mol. Med."},{"key":"ref_11","first-page":"61","article-title":"Mechanisms of antimicrobial resistance in Gram-negative bacilli","volume":"5","author":"Woerther","year":"2015","journal-title":"Ann. Intensive Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/1469-0691.12655","article-title":"Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species","volume":"20","author":"Diene","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Eichenberger, E.M., and Thaden, J.T. (2019). Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria. Antibiotics, 8.","DOI":"10.3390\/antibiotics8020037"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: The versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2016.09.002","article-title":"The rapid spread of carbapenem-resistant Enterobacteriaceae","volume":"29","author":"Potter","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/jac\/dkae265","article-title":"The contribution of porins to enterobacterial drug resistance","volume":"79","author":"Vergalli","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e0121425","DOI":"10.1128\/aac.01214-25","article-title":"Carbapenem resistance in a Klebsiella quasipneumoniae isolate resulting from production of CTX-M-33 and OmpK36 porin deficiency","volume":"6","author":"Findlay","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ijantimicag.2018.03.020","article-title":"Role of association of OmpK35 and OmpK36 alteration and blaESBL and\/or blaAmpC genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae","volume":"52","author":"Hamzaoui","year":"2018","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_19","first-page":"1143","article-title":"Mechanism for carbapenem resistance of clinical Enterobacteriaceae isolates","volume":"15","author":"Ye","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.50.5.1633-1641.2006","article-title":"Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates","volume":"50","author":"Quale","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00203-016-1215-7","article-title":"Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa","volume":"198","author":"Pan","year":"2016","journal-title":"Arch. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e0014825","DOI":"10.1128\/jb.00148-25","article-title":"Molecular characterization and resistance mechanisms of ertapenem-non-susceptible carbapenem-resistant Klebsiella pneumoniae co-harboring ESBLs or AmpC enzymes with porin loss or efflux pump overexpression","volume":"207","author":"Su","year":"2025","journal-title":"J. Bacteriol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rahmat Ullah, S., Irum, S., Mahnoor, I., Ismatullah, H., Mumtaz, M., Andleeb, S., Rahman, A., and Jamal, M. (2024). Exploring the resistome, virulome, and mobilome of multidrug-resistant Klebsiella pneumoniae isolates: Deciphering the molecular basis of carbapenem resistance. BMC Genom., 25.","DOI":"10.1186\/s12864-024-10139-y"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1128\/AAC.43.7.1669","article-title":"Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae","volume":"43","author":"Pascual","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/QCO.0000000000000608","article-title":"Epidemiology of carbapenem-resistant Gram-negative infections globally","volume":"32","author":"Brink","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e054971","DOI":"10.1136\/bmjopen-2021-054971","article-title":"Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: A systematic review and meta-analysis","volume":"11","author":"Zhou","year":"2021","journal-title":"BMJ Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"107769","DOI":"10.1016\/j.ijid.2024.107769","article-title":"Global and regional burden of bloodstream infections caused by carbapenem-resistant Gram-negative bacteria in 2019: A systematic analysis from the MICROBE database","volume":"153","author":"Zha","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Li, D., Huang, X., Rao, H., Yu, H., Long, S., Li, Y., and Zhang, J. (2023). Klebsiella pneumoniae bacteremia mortality: A systematic review and meta-analysis. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1157010"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jointm.2023.11.007","article-title":"Risk factors and mortality rates of carbapenem-resistant Gram-negative bacterial infections in intensive care units","volume":"4","author":"Kuloglu","year":"2024","journal-title":"J. Intensive Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Imai, S., Inoue, N., and Nagai, H. (2022). Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: A retrospective study using electronic medical records in Japan. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07548-3"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","article-title":"Risk factors for carbapenem-resistant Gram-negative bacterial infections: A systematic review","volume":"27","author":"Giannella","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41598-023-51118-9","article-title":"Comparison of mortality rates in patients with carbapenem-resistant Enterobacterales bacteremia according to carbapenemase production: A multicenter propensity-score matched study","volume":"14","author":"Baek","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.7326\/ANNALS-25-02404","article-title":"Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019 to 2023","volume":"178","author":"Rankin","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"ref_34","first-page":"507","article-title":"The Intriguing Carbapenemases of Pseudomonas aeruginosa: Current Status, Genetic Profile, and Global Epidemiology","volume":"95","year":"2022","journal-title":"Yale J. Biol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13643-025-02776-5","article-title":"Prevalence and molecular epidemiology of carbapenem resistance in Asia: A systematic review and meta-analysis","volume":"14","author":"Jayathilaka","year":"2025","journal-title":"Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"107449","DOI":"10.1016\/j.ijantimicag.2025.107449","article-title":"Epidemiology and outcomes associated with MBL-producing Enterobacterales: A systematic literature review","volume":"65","author":"Kanj","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-Producing Organisms: A Global Scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","article-title":"A functional classification scheme for beta-lactamases and its correlation with molecular structure","volume":"39","author":"Bush","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1128\/AAC.01019-15","article-title":"Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance","volume":"59","author":"Pitout","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2174\/1389450117666160310144501","article-title":"Structural and Functional Aspects of Class A Carbapenemases","volume":"17","author":"Naas","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00047-19","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of \u03b2-Lactamase-Producing Pathogen","volume":"33","author":"Bush","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bonnin, R.A., Jousset, A.B., Emeraud, C., Oueslati, S., Dortet, L., and Naas, T. (2021). Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales. Front. Med., 7.","DOI":"10.3389\/fmed.2020.616490"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jac\/dkaf121","article-title":"Detection of a novel SME-6 Carbapenemase in Serratia ureilytica in Germany","volume":"80","author":"Kocer","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1128\/AAC.44.11.3035-3039.2000","article-title":"SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains","volume":"44","author":"Queenan","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","article-title":"Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae","volume":"45","author":"Yigit","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1473-3099(09)70054-4","article-title":"The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria","volume":"9","author":"Nordmann","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1128\/AAC.00693-09","article-title":"Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase","volume":"54","author":"Bethel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e0200020","DOI":"10.1128\/AAC.02000-20","article-title":"Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017","volume":"65","author":"Kazmierczak","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/AAC.35.1.147","article-title":"Transferable imipenem resistance in Pseudomonas aeruginosa","volume":"35","author":"Watanabe","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"107421","DOI":"10.1016\/j.ijantimicag.2024.107421","article-title":"Integrons are key players in the spread of beta-lactamase-encoding genes","volume":"65","author":"Tavares","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.02379-15","article-title":"Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-\u03b2-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"60","author":"Kazmierczak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41467-025-66874-7","article-title":"The rise and global spread of IMP carbapenemases (1996\u20132023): A genomic epidemiology study","volume":"17","author":"Vezina","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.tim.2011.09.005","article-title":"The emerging NDM carbapenemases","volume":"19","author":"Nordmann","year":"2011","journal-title":"Trends Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.00774-09","article-title":"Characterization of a new metallo-beta-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India","volume":"53","author":"Yong","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/AAC.43.7.1584","article-title":"Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate","volume":"43","author":"Lauretti","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1128\/AAC.44.4.891-897.2000","article-title":"Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France","volume":"44","author":"Poirel","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jgar.2025.05.023","article-title":"Epidemiological insights into global metallo-\u03b2-lactamases-producing pseudomonas aeruginosa: A comprehensive analysis based on NCBI database","volume":"44","author":"Zhai","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/CMR.00117-13","article-title":"OXA \u03b2-lactamases","volume":"27","author":"Evans","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0924-8579(93)90045-7","article-title":"ARI 1: Beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii","volume":"2","author":"Paton","year":"1993","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1128\/AAC.44.1.196-199.2000","article-title":"Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92","volume":"44","author":"Donald","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.01512-08","article-title":"Diversity, epidemiology, and genetics of class D \u03b2-lactamases","volume":"54","author":"Poirel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chembiol.2013.07.015","article-title":"Structural basis for carbapenemase activity of the OXA-23 \u03b2-lactamase from Acinetobacter baumannii","volume":"20","author":"Smith","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.44.6.1556-1561.2000","article-title":"OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain","volume":"44","author":"Bou","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/AAC.49.10.4174-4179.2005","article-title":"Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii","volume":"49","author":"Poirel","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1469-0691.2006.01456.x","article-title":"Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology","volume":"12","author":"Poirel","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.49.1.202-208.2005","article-title":"OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii","volume":"49","author":"Poirel","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/AAC.48.1.15-22.2004","article-title":"Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae","volume":"48","author":"Poirel","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1128\/AAC.05289-11","article-title":"Genetic features of the widespread plasmid coding for the carbapenemase OXA-48","volume":"56","author":"Poirel","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e00102-19","DOI":"10.1128\/CMR.00102-19","article-title":"The Global Ascendency of OXA-48-Type Carbapenemases","volume":"33","author":"Pitout","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1038\/s41598-020-66431-w","article-title":"The hydrolytic water molecule of Class A \u03b2-lactamase relies on the acyl-enzyme intermediate ES* for proper coordination and catalysis","volume":"10","author":"He","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1128\/AAC.34.5.755","article-title":"Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates","volume":"34","author":"Yang","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1128\/AAC.38.6.1262","article-title":"Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6","volume":"38","author":"Naas","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/jac\/dkaf072","article-title":"First report of SME-carbapenemase-producing Serratia marcescens in France","volume":"80","author":"Robert","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"dlad126","DOI":"10.1093\/jacamr\/dlad126","article-title":"Serratia marcescens enzyme SME-2 isolated from sputum in New Zealand","volume":"5","author":"Creighton","year":"2023","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_76","first-page":"251","article-title":"First nosocomial outbreak of SME-4-producing Serratia marcescens in South America","volume":"55","author":"Vega","year":"2023","journal-title":"Rev. Argent. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1128\/AAC.40.9.2080","article-title":"Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae","volume":"40","author":"Rasmussen","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1128\/AAC.05478-11","article-title":"First detection of blaIMI-2 gene in a clinical Escherichia coli strain","volume":"56","author":"Torres","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/jac\/dkx103","article-title":"IMI-2 carbapenemase in a clinical Klebsiella variicola isolated in the UK","volume":"72","author":"Hopkins","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2217\/fmb.12.61","article-title":"Enterobacter cloacae complex: Clinical impact and emerging antibiotic resistance","volume":"7","author":"Mezzatesta","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e02578-16","DOI":"10.1128\/AAC.02578-16","article-title":"Enterobacter cloacae Complex Isolates Harboring blaNMC-A or blaIMI-Type Class A Carbapenemase Genes on Novel Chromosomal Integrative Elements and Plasmids","volume":"61","author":"Boyd","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6620","DOI":"10.1128\/AAC.01452-15","article-title":"Characterization of a Novel Putative Xer-Dependent Integrative Mobile Element Carrying the blaNMC-A Carbapenemase Gene, Inserted into the Chromosome of Members of the Enterobacter cloacae Complex","volume":"59","author":"Antonelli","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3201\/eid1102.030684","article-title":"Carbapenemase-producing Enterobacteriaceae, U.S. rivers","volume":"11","author":"Aubron","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s10096-025-05131-7","article-title":"Genomic comparative analysis of Enterobacter asburiae harbouring a conjugative blaIMI-6-plasmid isolated from a public garden in Switzerland","volume":"44","author":"Spahr","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jgar.2025.04.004","article-title":"First identification and whole-genome characterization of human-associated Enterobacter roggenkampii and Enterobacter sichuanensis carrying blaIMI-4 carbapenemase in Costa Rica","volume":"43","author":"Melano","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_86","first-page":"001919","article-title":"Nosocomial cluster of patients infected with imipenemase-1-producing Enterobacter ludwigii","volume":"73","author":"Horcajada","year":"2024","journal-title":"J. Med. Microbiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13756-021-01036-0","article-title":"A hospital-wide outbreak of IMI-17-producing Enterobacter ludwigii in an Israeli hospital","volume":"10","author":"Schechner","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Piedra-Carrasco, N., F\u00e0brega, A., Calero-C\u00e1ceres, W., Cornejo-S\u00e1nchez, T., Brown-Jaque, M., Mir-Cros, A., Muniesa, M., and Gonz\u00e1lez-L\u00f3pez, J.J. (2017). Carbapenemase-producing Enterobacteriaceae recovered from a Spanish river ecosystem. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175246"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"178300","DOI":"10.1016\/j.scitotenv.2024.178300","article-title":"Neglected class A carbapenemases: Systematic review of IMI\/NmcA and FRI from a One Health perspective","volume":"959","author":"Martel","year":"2025","journal-title":"Sci. Total Environ."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e0285322","DOI":"10.1128\/spectrum.02853-22","article-title":"Emergence of blaIMI-2- and blaIMI-16-Producing Enterobacter asburiae in the Aquaculture Environment of Jiangsu, China","volume":"11","author":"Che","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/jac\/dkac029","article-title":"Emergence of rare carbapenemases (FRI, GES-5, IMI, SFC and SFH-1) in Enterobacterales isolated from surface waters in Japan","volume":"77","author":"Gomi","year":"2022","journal-title":"Antimicrob. Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jgar.2018.06.022","article-title":"Transmission of IMI-2 carbapenemase-producing Enterobacteriaceae from river water to human","volume":"15","author":"Laurens","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1086\/647837","article-title":"Antimicrobial use and resistance in eight US hospitals: Complexities of analysis and modeling. Intensive Care Antimicrobial Resistance Epidemiology Project and National Nosocomial Infections Surveillance System Hospitals","volume":"19","author":"Monnet","year":"1998","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e0000823","DOI":"10.1128\/cmr.00008-23","article-title":"Klebsiella pneumoniae carbapenemase variants: The new threat to global public health","volume":"36","author":"Ding","year":"2023","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Falagas, M.E., Asimotou, C.M., Zidrou, M., Kontogiannis, D.S., and Filippou, C. (2025). Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review. Microorganisms, 13.","DOI":"10.3390\/microorganisms13071697"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e0044722","DOI":"10.1128\/aac.00447-22","article-title":"Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: An Evolutionary Overview","volume":"66","author":"Hobson","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"11223","DOI":"10.1038\/s41598-019-47758-5","article-title":"Assessing genetic diversity and similarity of 435 KPC-carrying plasmids","volume":"9","author":"Brandt","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Poirel","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1038\/s41467-024-49349-z","article-title":"International and regional spread of carbapenem-resistant Klebsiella pneumoniae in Europe","volume":"15","author":"Kostyanev","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"dlac098","DOI":"10.1093\/jacamr\/dlac098","article-title":"Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime\/avibactam and comparator agents","volume":"4","author":"Castanheira","year":"2022","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"401","DOI":"10.15585\/mmwr.mm7423a2","article-title":"Notes from the Field: Increase in New Delhi Metallo-\u03b2-Lactamase-Producing Carbapenem-Resistant Enterobacterales\u2014New York City, 2019\u20132024","volume":"74","author":"Devinney","year":"2025","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e0120524","DOI":"10.1128\/aac.01205-24","article-title":"Multispecies emergence of dual blaKPC\/NDM carbapenemase-producing Enterobacterales recovered from invasive infections in Chile","volume":"69","author":"Solar","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Huang, J., Zhang, S., Zhao, Z., Chen, M., Cao, Y., and Li, B. (2021). Acquisition of a Stable and Transferable blaNDM-5-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime\/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.658070"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jgar.2020.01.021","article-title":"Unravelling the genome sequence of NDM-1 and KPC-2 co-producing Klebsiella pneumoniae ST11 isolated from a bloodstream infection","volume":"20","author":"Xu","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jgar.2022.04.006","article-title":"Coexistence of two blaKPC-2 genes in a blaNDM-1-carrying multidrug-resistant ST15 Klebsiella pneumoniae isolate recovered from cerebrospinal fluid in China","volume":"29","author":"Sun","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"102599","DOI":"10.1016\/j.ebiom.2019.102599","article-title":"The transferability and evolution of NDM-1 and KPC-2 co-producing Klebsiella pneumoniae from clinical setting","volume":"51","author":"Gao","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"128049","DOI":"10.1016\/j.micres.2025.128049","article-title":"Rapid emergence, transmission, and evolution of KPC and NDM coproducing carbapenem-resistant Klebsiella pneumoniae","volume":"293","author":"Li","year":"2025","journal-title":"Microbiol. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2147\/IDR.S523271","article-title":"Co-Production of KPC-2 and NDM-5 in a Carbapenem-Resistant Klebsiella Pneumoniae Clinical Isolate: Genetic Insights and Risks","volume":"18","author":"Xia","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Chatzidimitriou, M., Voulgaridis, A., Tsolakidou, P., Chatzopoulou, F., Chonianakis, I., Vagdatli, E., Kachrimanidou, M., and Vyzantiadis, T.A. (2025). Significant Prevalence of Dual KPC\/NDM Carbapenemase-Producing Klebsiella pneumoniae in an ICU Cohort in Thessaloniki (2023), Including an ST512 Isolate Co-Harboring blaNDM-1 and blaKPC-3. Antibiotics, 14.","DOI":"10.3390\/antibiotics14100994"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"117035","DOI":"10.1016\/j.diagmicrobio.2025.117035","article-title":"Carriage and infections by multi-carbapenemases producing Enterobacterales","volume":"113","author":"Boattini","year":"2025","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Mohamed, E.R., Ali, M.Y., Waly, N.G.F.M., Halby, H.M., and El-Baky, R.M.A. (2019). The Inc FII Plasmid and its Contribution in the Transmission of blaNDM-1 and blaKPC-2 in Klebsiella pneumoniae in Egypt. Antibiotics, 8.","DOI":"10.3390\/antibiotics8040266"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Rodrigues, Y.C., Lobato, A.R.F., Quaresma, A.J.P.G., Guerra, L.M.G.D., and Brasiliense, D.M. (2021). The Spread of NDM-1 and NDM-7-Producing Klebsiella pneumoniae Is Driven by Multiclonal Expansion of High-Risk Clones in Healthcare Institutions in the State of Par\u00e1, Brazilian Amazon Region. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121527"},{"key":"ref_114","first-page":"288","article-title":"Emergence and clonal expansion of Klebsiella pneumoniae ST307, simultaneously producing KPC-3 and NDM-1","volume":"54","author":"Cejas","year":"2022","journal-title":"Rev. Argent. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"105795","DOI":"10.1016\/j.meegid.2025.105795","article-title":"Plasmid diversity in Klebsiella pneumoniae ST307 co-producing KPC plus NDM recovered during the COVID-19 pandemic","volume":"133","author":"Gomez","year":"2025","journal-title":"Infect. Genet. Evol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"\u015eanl\u0131, K., and \u00d6ncel, B. (2025). Analysis of rectal carbapenem-resistant Enterobactericeae colonization results first report in Istanbul\/Turkiye: Klebsiella pneumoniae co-producing blaKPC + blaNDM + blaOXA-48 in a single strain. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-11111-1"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e0012625","DOI":"10.1128\/spectrum.00126-25","article-title":"Antimicrobial resistance and phylogenetic lineages of KPC-2-producing blood-borne Klebsiella pneumoniae subsp. pneumoniae from Kolkata, India during 2015-2024: Emergence of Klebsiella pneumoniae subsp. pneumoniae with blaKPC-2, blaNDM, and blaOXA-48-like triple carbapenemases","volume":"13","author":"Halder","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1128\/AAC.43.4.902","article-title":"Biochemical characterization of the Pseudomonas aeruginosa 101\/1477 metallo-beta-lactamase IMP-1 produced by Escherichia coli","volume":"43","author":"Laraki","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/AAC.38.1.71","article-title":"Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance","volume":"38","author":"Osano","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1128\/AAC.39.7.1612","article-title":"A novel integron-like element carrying the metallo-beta-lactamase gene blaIMP","volume":"39","author":"Arakawa","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00716-13","article-title":"IMP-43 and IMP-44 metallo-\u03b2-lactamases with increased carbapenemase activities in multidrug-resistant Pseudomonas aeruginosa","volume":"57","author":"Tada","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jmb.2006.11.027","article-title":"Hydroxyl groups in the betabeta sandwich of metallo-beta-lactamases favor enzyme activity: Tyr218 and Ser262 pull down the lid","volume":"366","author":"Oelschlaeger","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e01714-20","DOI":"10.1128\/AAC.01714-20","article-title":"Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants","volume":"65","author":"Cheng","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e02729-16","DOI":"10.1128\/AAC.02729-16","article-title":"Global Molecular Epidemiology of IMP-Producing Enterobacteriaceae","volume":"61","author":"Matsumura","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1128\/JCM.43.8.3824-3828.2005","article-title":"Nosocomial outbreak caused by multidrug-resistant Pseudomonas aeruginosa producing IMP-13 metallo-beta-lactamase","volume":"43","author":"Pagani","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1017\/ice.2023.75","article-title":"Molecular characterization of a suspected IMP-type carbapenemase-producing Pseudomonas aeruginosa outbreak reveals two simultaneous outbreaks in a tertiary-care hospital","volume":"44","author":"Oliver","year":"2023","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/jac\/dkw165","article-title":"Outbreak of IMP-producing carbapenem-resistant Enterobacter gergoviae among kidney transplant recipients","volume":"71","author":"Freire","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e14414","DOI":"10.1111\/tid.14414","article-title":"Recurrent Outbreak of Carbapenem-Resistant IMP-1-Producing Pseudomonas aeruginosa in Kidney Transplant Recipients: The Impact of Prolonged Patient Colonization","volume":"27","author":"Freire","year":"2025","journal-title":"Transpl. Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2147\/IDR.S174869","article-title":"First reported nosocomial outbreak of Serratia marcescens harboring blaIMP-4 and blaVIM-2 in a neonatal intensive care unit in Cairo, Egypt","volume":"11","author":"Ghaith","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1128\/AAC.04378-14","article-title":"Dominance of IMP-4-producing Enterobacter cloacae among carbapenemase-producing Enterobacteriaceae in Australia","volume":"59","author":"Sidjabat","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/1469-0691.12719","article-title":"The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide","volume":"20","author":"Nordmann","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1128\/AAC.00585-11","article-title":"Genetic features of blaNDM-1-positive Enterobacteriaceae","volume":"55","author":"Poirel","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1099\/jmm.0.052555-0","article-title":"Global spread of antibiotic resistance: The example of New Delhi metallo-\u03b2-lactamase (NDM)-mediated carbapenem resistance","volume":"62","author":"Johnson","year":"2013","journal-title":"J. Med. Microbiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1128\/AAC.05961-11","article-title":"NDM-4 metallo-\u03b2-lactamase with increased carbapenemase activity from Escherichia coli","volume":"56","author":"Nordmann","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Cuzon, G., Bonnin, R.A., and Nordmann, P. (2013). First identification of novel NDM carbapenemase, NDM-7, in Escherichia coli in France. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061322"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/jac\/dkt088","article-title":"Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-\u03b2-lactamase with increased carbapenemase activity","volume":"68","author":"Hamprecht","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijantimicag.2014.03.003","article-title":"Prevalence and molecular characterisation of New Delhi metallo-\u03b2-lactamases NDM-1, NDM-5, NDM-6 and NDM-7 in multidrug-resistant Enterobacteriaceae from India","volume":"44","author":"Rahman","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acsinfecdis.7b00128","article-title":"Clinical Variants of New Delhi Metallo-\u03b2-Lactamase Are Evolving To Overcome Zinc Scarcity","volume":"3","author":"Stewart","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1021\/acsomega.3c07446","article-title":"Dinuclear Zn-Catalytic System as Br\u00f8nsted Base and Lewis Acid for Enantioselectivity in Same Chiral Environment","volume":"9","author":"Arshad","year":"2024","journal-title":"ACS Omega"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s40121-024-01044-8","article-title":"Navigating the Current Treatment Landscape of Metallo-\u03b2-Lactamase-Producing Gram-Negative Infections: What are the Limitations?","volume":"13","author":"Grabein","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Hu, Y., Yang, Y., Feng, Y., Fang, Q., Wang, C., Zhao, F., McNally, A., and Zong, Z. (2023). Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries. PLoS Med., 20.","DOI":"10.1371\/journal.pmed.1004233"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1473-3099(11)70059-7","article-title":"Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: An environmental point prevalence study","volume":"11","author":"Walsh","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.envint.2018.07.004","article-title":"Carbapenem resistance exposures via wastewaters across New Delhi","volume":"119","author":"Lamba","year":"2018","journal-title":"Environ. Int."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"104628","DOI":"10.1016\/j.idnow.2022.09.023","article-title":"The crisis of carbapenemase-mediated carbapenem resistance across the human-animal-environmental interface in India","volume":"53","author":"Das","year":"2023","journal-title":"Infect. Dis. Now"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/jac\/dkx148","article-title":"Genomic epidemiology of global VIM-producing Enterobacteriaceae","volume":"72","author":"Matsumura","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e0140622","DOI":"10.1128\/aac.01406-22","article-title":"Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Study, 2018 to 2019","volume":"67","author":"Estabrook","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/CMR.18.2.306-325.2005","article-title":"Metallo-beta-lactamases: The quiet before the storm?","volume":"18","author":"Walsh","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13756-025-01599-2","article-title":"Protracted outbreaks of VIM-producing Pseudomonas aeruginosa in a surgical intensive care unit in France, January 2018 to June 2024","volume":"14","author":"Querin","year":"2025","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2023.06.003","article-title":"Association of Artificial Tears with Ocular and Systemic Infection: Carbapenem-resistant Pseudomonas aeruginosa (VIM-GES-CRPA) Outbreak","volume":"130","author":"Velcani","year":"2023","journal-title":"Ophthalmology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e0147423","DOI":"10.1128\/aac.01474-23","article-title":"Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-\u03b2-lactamase (blaVIM): Infection management and molecular analysis","volume":"68","author":"Vega","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1017\/ice.2023.231","article-title":"Concurrent transmission of multiple carbapenemases in a long-term acute-care hospital","volume":"45","author":"Rankin","year":"2024","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.ajic.2024.08.022","article-title":"Five-year VIM-producing Pseudomonas aeruginosa outbreak in four Belgian ICUs, an investigation report (2019\u20132023)","volume":"52","author":"Moretti","year":"2024","journal-title":"Am. J. Infect. Control"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jhin.2023.10.010","article-title":"Long-term intensive care unit outbreak of carbapenemase-producing organisms associated with contaminated sink drains","volume":"143","author":"Anantharajah","year":"2024","journal-title":"J. Hosp. Infect."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e0074024","DOI":"10.1128\/spectrum.00740-24","article-title":"Three prolonged outbreaks of metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa in an Upper Austrian hospital, 2017\u20132023","volume":"12","author":"Cabal","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Fraenkel, C.J., Starlander, G., Tano, E., S\u00fctterlin, S., and Melhus, \u00c5. (2023). The First Swedish Outbreak with VIM-2-Producing Pseudomonas aeruginosa, Occurring between 2006 and 2007, Was Probably Due to Contaminated Hospital Sinks. Microorganisms, 11.","DOI":"10.3390\/microorganisms11040974"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s13054-021-03726-y","article-title":"Outbreak of Pseudomonas aeruginosa producing VIM carbapenemase in an intensive care unit and its termination by implementation of waterless patient care","volume":"25","author":"Catho","year":"2021","journal-title":"Crit. Care"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"21015","DOI":"10.1038\/s41598-021-00205-w","article-title":"National surveillance pilot study unveils a multicenter, clonal outbreak of VIM-2-producing Pseudomonas aeruginosa ST111 in the Netherlands between 2015 and 2017","volume":"11","author":"Pirzadian","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Yao, Y., Falgenhauer, L., Falgenhauer, J., Hauri, A.M., Heinm\u00fcller, P., Domann, E., Chakraborty, T., and Imirzalioglu, C. (2021). Carbapenem-Resistant Citrobacter spp. as an Emerging Concern in the Hospital-Setting: Results From a Genome-Based Regional Surveillance Study. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.744431"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e00275-20","DOI":"10.1128\/JCM.00275-20","article-title":"Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades","volume":"58","author":"Babiker","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e0414422","DOI":"10.1128\/spectrum.04144-22","article-title":"Molecular Epidemiology of Global Carbapenemase-Producing Citrobacter spp. (2015\u20132017)","volume":"11","author":"Nobrega","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/AAC.46.6.2004-2006.2002","article-title":"Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis","volume":"46","author":"Bonnet","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1128\/AAC.03119-15","article-title":"Rare Detection of the Acinetobacter Class D Carbapenemase blaOXA-23 Gene in Proteus mirabilis","volume":"60","author":"Karah","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e0198321","DOI":"10.1128\/aac.01983-21","article-title":"High Prevalence of OXA-23 Carbapenemase-Producing Proteus mirabilis among Amoxicillin-Clavulanate-Resistant Isolates in France","volume":"66","author":"Lombes","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Shahid, M., Ahmad, N., Saeed, N.K., Shadab, M., Joji, R.M., Al-Mahmeed, A., Bindayna, K.M., Tabbara, K.S., and Dar, F.K. (2022). Clinical carbapenem-resistant Klebsiella pneumoniae isolates simultaneously harboring blaNDM-1, blaOXA types and qnrS genes from the Kingdom of Bahrain: Resistance profile and genetic environment. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.1033305"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3201\/eid1601.090852","article-title":"Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii","volume":"16","author":"Mugnier","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/jac\/dki482","article-title":"OXA-type carbapenemases","volume":"57","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/AAC.45.2.583-588.2001","article-title":"Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii","volume":"45","author":"Woodford","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.3390\/ijerph120810079","article-title":"Prevalence of Genes of OXA-23 Carbapenemase and AdeABC Efflux Pump Associated with Multidrug Resistance of Acinetobacter baumannii Isolates in the ICU of a Comprehensive Hospital of Northwestern China","volume":"12","author":"Jia","year":"2015","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Fonseca, E.L., Scheidegger, E., Freitas, F.S., Cipriano, R., and Vicente, A.C. (2013). Carbapenem-resistant Acinetobacter baumannii from Brazil: Role of carO alleles expression and blaOXA-23 gene. BMC Microbiol., 13.","DOI":"10.1186\/1471-2180-13-245"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1128\/AAC.49.8.3198-3202.2005","article-title":"Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii","volume":"49","author":"Poirel","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1128\/AAC.00267-07","article-title":"Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital","volume":"51","author":"Quinteira","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.patbio.2008.05.002","article-title":"First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii","volume":"57","author":"Sevillano","year":"2009","journal-title":"Pathol. Biol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.2147\/IDR.S386641","article-title":"Molecular Characterization of Carbapenem-Resistant Acinetobacter baumannii with Special Reference to Carbapenemases: A Systematic Review","volume":"15","author":"Gupta","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1128\/AAC.03651-14","article-title":"Common clinical substitutions enhance the carbapenemase activity of OXA-51-like class D \u03b2-lactamases from Acinetobacter spp.","volume":"58","author":"Mitchell","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jac\/dkaa502","article-title":"Variability in carbapenemase activity of intrinsic OxaAb (OXA-51-like) \u03b2-lactamase enzymes in Acinetobacter baumannii","volume":"76","author":"Takebayashi","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1128\/AAC.00622-11","article-title":"Emergence of carbapenem-resistant non-baumannii species of Acinetobacter harboring a blaOXA-51-like gene that is intrinsic to A. baumannii","volume":"56","author":"Lee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/JCM.00832-13","article-title":"Identification of blaOXA-51-like, blaOXA-58, blaDIM-1, and blaVIM carbapenemase genes in hospital Enterobacteriaceae isolates from Sierra Leone","volume":"51","author":"Leski","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1574-6968.2006.00195.x","article-title":"The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii","volume":"258","author":"Turton","year":"2006","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bjm.2016.06.005","article-title":"Mobile genetic elements related to carbapenem resistance in Acinetobacter baumannii","volume":"47","author":"Pagano","year":"2016","journal-title":"Braz. J. Microbiol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1128\/AAC.01132-06","article-title":"Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii","volume":"51","author":"Corvec","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1590\/0037-8682-0002-2016","article-title":"The role of the genetic elements blaoxa and IS Aba 1 in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex in carbapenem resistance in the hospital setting","volume":"49","author":"Kobs","year":"2016","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1128\/AAC.50.4.1442-1448.2006","article-title":"Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-58 in Acinetobacter baumannii","volume":"50","author":"Poirel","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e02633-18","DOI":"10.1128\/AAC.02633-18","article-title":"Emergence of IMP-34- and OXA-58-Producing Carbapenem-Resistant Acinetobacter colistiniresistens","volume":"63","author":"Suzuki","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"116246","DOI":"10.1016\/j.diagmicrobio.2024.116246","article-title":"Identification of Providencia spp. clinical isolates co-producing carbapenemases IMP-27, OXA-24, and OXA-58 in Mexico","volume":"109","year":"2024","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e0020622","DOI":"10.1128\/aac.00206-22","article-title":"Coexistence of blaOXA-58 and blaNDM-1 on a Novel Plasmid of GR59 from an Acinetobacter towneri Isolate","volume":"66","author":"Li","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_187","first-page":"106","article-title":"Detection of co-harboring OXA-58 and NDM-1 carbapenemase producing genes resided on a same plasmid from an Acinetobacter pittii clinical isolate in China","volume":"22","author":"Chen","year":"2019","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Tian, C., Song, J., Ren, L., Huang, D., Wang, S., Fu, L., Zhao, Y., Bai, Y., Fan, X., and Ma, T. (2023). Complete genetic characterization of carbapenem-resistant Acinetobacter johnsonii, co-producing NDM-1, OXA-58, and PER-1 in a patient source. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1227063"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Rodrigues, D.C.S., Silveira, M.C., Pribul, B.R., Karam, B.R.S., Pic\u00e3o, R.C., Kraychete, G.B., Pereira, F.M., de Lima, R.M., de Souza, A.K.G., and Le\u00e3o, R.S. (2024). Genomic study of Acinetobacter baumannii strains co-harboring blaOXA-58 and blaNDM-1 reveals a large multidrug-resistant plasmid encoding these carbapenemases in Brazil. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1439373"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"116428","DOI":"10.1016\/j.diagmicrobio.2024.116428","article-title":"An outbreak of severe or lethal infections by a multidrug-resistant Acinetobacter baumannii ST126 strain carrying a plasmid with blaNDM-1 and blaOXA-58 carbapenemases","volume":"110","year":"2024","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e00184-21","DOI":"10.1128\/AAC.00184-21","article-title":"Antimicrobial Resistance Conferred by OXA-48 \u03b2-Lactamases: Towards a Detailed Mechanistic Understanding","volume":"65","author":"Hirvonen","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Nicolas-Chanoine, M.H., Mayer, N., Guyot, K., Dumont, E., and Pag\u00e8s, J.M. (2018). Interplay Between Membrane Permeability and Enzymatic Barrier Leads to Antibiotic-Dependent Resistance in Klebsiella pneumoniae. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.01422"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e0010725","DOI":"10.1128\/aac.00107-25","article-title":"Proteogenomic analysis demonstrates increased blaOXA-48 copy numbers and OmpK36 loss as contributors to carbapenem resistance in Klebsiella pneumoniae","volume":"69","author":"Meekes","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/AAC.01344-13","article-title":"Derepressed transfer properties leading to the efficient spread of the plasmid encoding carbapenemase OXA-48","volume":"58","author":"Potron","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"20549","DOI":"10.2807\/1560-7917.ES2013.18.31.20549","article-title":"Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011","volume":"18","author":"Potron","year":"2013","journal-title":"Euro Surveill."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/JCM.02316-16","article-title":"In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014","volume":"55","author":"Karlowsky","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e00592-18","DOI":"10.1128\/AAC.00592-18","article-title":"In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/8755122520934726","article-title":"Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem\/Cilastatin-Relebactam to Target Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales","volume":"36","author":"Hayden","year":"2020","journal-title":"J. Pharm. Technol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: A novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against Class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13756-025-01518-5","article-title":"Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: Systematic review and meta-analysis","volume":"14","author":"Wang","year":"2025","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid \u03b2-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1060028018763288","article-title":"Meropenem\/Vaborbactam, the First Carbapenem\/\u03b2-Lactamase Inhibitor Combination","volume":"52","author":"Cho","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e01904-17","DOI":"10.1128\/AAC.01904-17","article-title":"In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae","volume":"62","author":"Hackel","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e01443-17","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/phar.2378","article-title":"Imipenem-Cilastatin-Relebactam: A Novel \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections","volume":"40","author":"Smith","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-\u03b2-Lactamase Inhibitor Combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"ref_211","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/IDR.S224228","article-title":"A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date","volume":"13","author":"Campanella","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e0091822","DOI":"10.1128\/aac.00918-22","article-title":"In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae","volume":"66","author":"Findlay","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e0019122","DOI":"10.1128\/aac.00191-22","article-title":"Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem\/Relebactam and Meropenem\/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate","volume":"66","author":"Gaibani","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/fmb-2023-0248","article-title":"Sulbactam-durlobactam: A \u03b2-lactam\/\u03b2-lactamase inhibitor combination targeting Acinetobacter baumannii","volume":"19","author":"McLeod","year":"2024","journal-title":"Future Microbiol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/Durlobactam: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1093\/jac\/dkad244","article-title":"In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales","volume":"78","author":"Fouad","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Guler","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: A multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/17460913.2025.2468112","article-title":"Cefepime-enmetazobactam: First approved cefepime-\u03b2-lactamase inhibitor combination for multi-drug resistant Enterobacterales","volume":"20","author":"Bhowmick","year":"2025","journal-title":"Future Microbiol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40265-024-02035-2","article-title":"Cefepime\/Enmetazobactam: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"e00105-19","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combination","volume":"63","author":"Bethel","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/17425255.2024.2427310","article-title":"Cefepime\/Enmetazobactam: A microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation","volume":"21","author":"Darlow","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cmi.2024.09.031","article-title":"In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives","volume":"31","author":"Bonnin","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"e00514-19","DOI":"10.1128\/AAC.00514-19","article-title":"In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014\u20132015","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s10096-025-05080-1","article-title":"In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-\u03b2-lactamase producers","volume":"44","author":"Boattini","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e01856-17","DOI":"10.1128\/AAC.01856-17","article-title":"Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates","volume":"62","author":"Sader","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"e00472-17","DOI":"10.1128\/AAC.00472-17","article-title":"In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"ofaf250","DOI":"10.1093\/ofid\/ofaf250","article-title":"Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017\u20132022)","volume":"12","author":"Sader","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): A descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"106776","DOI":"10.1016\/j.ijantimicag.2023.106776","article-title":"Activity of aztreonam\/avibactam against metallo-\u03b2-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 \u03b2-lactamase in Escherichia coli","volume":"61","author":"Livermore","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","article-title":"Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-\u03b2-Lactamases","volume":"62","author":"Krajnc","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"e01963-19","DOI":"10.1128\/AAC.01963-19","article-title":"VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-\u03b2-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa","volume":"64","author":"Hamrick","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40265-024-02082-9","article-title":"Cefepime-Taniborbactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination","volume":"84","author":"Zhanel","year":"2024","journal-title":"Drugs"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"CERTAIN-1 Study Team. Cefepime-Taniborbactam in Complicated Urinary Tract Infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkae329","article-title":"Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018\u201322","volume":"79","author":"Karlowsky","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"e0114424","DOI":"10.1128\/spectrum.01144-24","article-title":"Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with blaOXA-48","volume":"12","author":"Mojica","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"e0116823","DOI":"10.1128\/aac.01168-23","article-title":"Structural basis of metallo-\u03b2-lactamase resistance to taniborbactam","volume":"68","author":"Drusin","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"e00072-17","DOI":"10.1128\/AAC.00072-17","article-title":"WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1093\/jac\/dkac233","article-title":"Antimicrobial activity of cefepime\/zidebactam (WCK 5222), a \u03b2-lactam\/\u03b2-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018\u201319)","volume":"77","author":"Sader","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"e01238-17","DOI":"10.1128\/AAC.01238-17","article-title":"Potent \u03b2-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_243","first-page":"322","article-title":"In vitro activity of Cefepime\/Enmetazobactam and Cefepime\/Zidebactam against OXA-48-producing Klebsiella pneumoniae clinical strains","volume":"48","author":"Bulfoni","year":"2025","journal-title":"New Microbiol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cid\/ciaf638","article-title":"First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa","volume":"82","author":"Dorazio","year":"2026","journal-title":"Clin. Infect. Dis."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.02704-15","article-title":"In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae","volume":"60","author":"Morinaka","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/jac\/dkad033","article-title":"Development of an optimized and practical pharmacokinetics\/pharmacodynamics analysis method for aztreonam\/nacubactam against carbapenemase-producing K. pneumoniae","volume":"78","author":"Igarashi","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/14787210.2024.2407068","article-title":"Novel agents in development for the treatment of resistant Gram-negative infections","volume":"22","author":"Bassetti","year":"2024","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"e0077524","DOI":"10.1128\/aac.00775-24","article-title":"Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone \u03b2-lactamase inhibitors against broad-spectrum AmpC \u03b2-lactamases","volume":"68","author":"Mlynarcik","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"e0075525","DOI":"10.1128\/aac.00755-25","article-title":"Evaluation of in vitro efficacy of aztreonam-nacubactam and cefepime-nacubactam against clinical isolates of Stenotrophomonas maltophilia","volume":"69","author":"Aoki","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1093\/jac\/dkad242","article-title":"Imipenem\/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: A novel modelling approach for time-dependent killing","volume":"78","author":"Fratoni","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Katsarou, A., Stathopoulos, P., Tzvetanova, I.D., Asimotou, C.M., and Falagas, M.E. (2025). \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination Antibiotics Under Development. Pathogens, 14.","DOI":"10.3390\/pathogens14020168"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/13543784.2025.2532443","article-title":"Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials","volume":"34","author":"Romanos","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/13543784.2025.2552846","article-title":"Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials","volume":"34","author":"Kontogiannis","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"e02596-17","DOI":"10.1128\/AAC.02596-17","article-title":"In Vivo Efficacy of Meropenem with a Novel Non-\u03b2-Lactam-\u03b2-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model","volume":"62","author":"Monogue","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dky522","article-title":"Activity of nacubactam (RG6080\/OP0595) combinations against MBL-producing Enterobacteriaceae","volume":"74","author":"Mushtaq","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"e0160223","DOI":"10.1128\/aac.01602-23","article-title":"In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-\u03b2-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria","volume":"68","author":"Takemoto","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1093\/jac\/dkac280","article-title":"Activity of ertapenem\/zidebactam (WCK 6777) against problem Enterobacterales","volume":"77","author":"Mushtaq","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"e0087922","DOI":"10.1128\/aac.00879-22","article-title":"Intrinsic Antibacterial Activity of Xeruborbactam In Vitro: Assessing Spectrum and Mode of Action","volume":"66","author":"Sun","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"e00212-20","DOI":"10.1128\/AAC.00212-20","article-title":"Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases","volume":"64","author":"Lomovskaya","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"e0044023","DOI":"10.1128\/aac.00440-23","article-title":"In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing Enterobacterales","volume":"67","author":"Lomovskaya","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_261","first-page":"e0157023","article-title":"Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-\u03b2-lactamases produced in Escherichia coli and Pseudomonas aeruginosa","volume":"68","author":"Freire","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_262","first-page":"e0029725","article-title":"The emerging concern of IMP variants being resistant to the only IMP-type metallo-\u03b2-lactamase inhibitor, xeruborbactam","volume":"69","author":"Drusin","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"15802","DOI":"10.1021\/acs.jmedchem.0c01535","article-title":"Discovery of ANT3310, a Novel Broad-Spectrum Serine \u03b2-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii","volume":"63","author":"Davies","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"e0112023","DOI":"10.1128\/aac.01120-23","article-title":"Meropenem-ANT3310, a unique \u03b2-lactam-\u03b2-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii","volume":"68","author":"Zalacain","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_265","first-page":"e0169125","article-title":"Disarming carbapenemase-producing Acinetobacter baumannii: High potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane \u03b2-lactamase inhibitor pilabactam (formerly ANT3310)","volume":"19","author":"Lence","year":"2026","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): A potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dkp197","article-title":"In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases","volume":"64","author":"Stachyra","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","article-title":"In vitro activity of avibactam (NXL104) in combination with \u03b2-lactams against Gram-negative bacteria, including OXA-48 \u03b2-lactamase-producing Klebsiella pneumoniae","volume":"39","author":"Kayacan","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): A randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Xie, X., Chen, J., Qi, L., Yuan, Y., Long, J., Wu, X., Liu, Y., Guo, J., Wang, C., and Meng, X. (2025). Global epidemiology and resistance-related mutations of ceftazidime-avibactam-resistant Klebsiella pneumoniae strains. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1645042"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/cid\/ciaa1521","article-title":"Emergence and Recovery of Ceftazidime-avibactam Resistance in blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China","volume":"71","author":"Shi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jgar.2021.04.001","article-title":"Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: A systematic review of observational clinical studies","volume":"25","author":"Giacobbe","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12941-025-00797-5","article-title":"Clinical and Microbiological characteristics of patients with ceftazidime\/avibactam-resistant Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains","volume":"24","author":"Liu","year":"2025","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.2147\/IDR.S470688","article-title":"A Novel Variant of KPC-179 Conferring Ceftazidime-Avibactam Resistance in a Carbapenem-Resistant Klebsiella pneumoniae Isolate","volume":"17","author":"Liao","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_277","doi-asserted-by":"crossref","unstructured":"Liu, Z., Lei, J., Zhang, X., Yin, J., Zhang, Y., Lei, K., Geng, Y., Huang, L., Han, Q., and He, A. (2025). Evolution of ceftazidime-avibactam resistance driven by variation in blaKPC-2 to blaKPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniae. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1607127"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"107411","DOI":"10.1016\/j.ijantimicag.2024.107411","article-title":"Characterization of a novel KPC-2 variant, KPC-228, conferring resistance to ceftazidime-avibactam in an ST11-KL64 hypervirulent Klebsiella pneumoniae","volume":"65","author":"Zhou","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"e0149424","DOI":"10.1128\/aac.01494-24","article-title":"Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime\/avibactam: The threat of de novo infections by ceftazidime\/avibactam-resistant KPC variants","volume":"69","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00203-025-04298-z","article-title":"Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: Action and resistance mechanisms","volume":"207","year":"2025","journal-title":"Arch. Microbiol."},{"key":"ref_281","unstructured":"United States Food and Drug Administration (2026, February 26). VABOMERE (Meropenem and Vaborbactam) for Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209776lbl.pdf."},{"key":"ref_282","unstructured":"European Medicines Agency (2026, February 26). Vaborem. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaborem."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/AAC.22.1.62","article-title":"Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase","volume":"22","author":"Kropp","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/jm00389a018","article-title":"Inhibition of the mammalian beta-lactamase renal dipeptidase (dehydropeptidase-I) by (Z)-2-(acylamino)-3-substituted-propenoic acids","volume":"30","author":"Graham","year":"1987","journal-title":"J. Med. Chem."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"e00642-17","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"e00533-18","DOI":"10.1128\/AAC.00533-18","article-title":"In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli","volume":"62","author":"Mishra","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"e00672-19","DOI":"10.1128\/AAC.00672-19","article-title":"Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae","volume":"63","author":"Canver","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1093\/cid\/ciad109","article-title":"Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex","volume":"76","author":"Castanheira","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_289","first-page":"37","article-title":"Sulbactam: A beta-lactamase inhibitor","volume":"7","author":"Noguchi","year":"1988","journal-title":"Clin. Pharm."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"e01612-17","DOI":"10.1128\/AAC.01612-17","article-title":"Kinetics of Sulbactam Hydrolysis by \u03b2-Lactamases, and Kinetics of \u03b2-Lactamase Inhibition by Sulbactam","volume":"61","author":"Shapiro","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/jac\/dkt275","article-title":"TEM-1 \u03b2-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii","volume":"68","author":"Krizova","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_293","doi-asserted-by":"crossref","unstructured":"Kuo, S.C., Lee, Y.T., Yang Lauderdale, T.L., Huang, W.C., Chuang, M.F., Chen, C.P., Su, S.C., Lee, K.R., and Chen, T.L. (2015). Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.00231"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jac\/dkaa511","article-title":"An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa","volume":"76","author":"Isler","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"dkaf440","DOI":"10.1093\/jac\/dkaf440","article-title":"In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales","volume":"81","author":"Dutkiewicz","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1128\/AAC.21.6.950","article-title":"Mode of action of azthreonam","volume":"21","author":"Georgopapadakou","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1016\/j.bmcl.2007.06.089","article-title":"A minimalistic approach to identify substrate binding features in B1 Metallo-beta-lactamases","volume":"17","author":"Tomatis","year":"2007","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1128\/AAC.00206-15","article-title":"In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013","volume":"59","author":"Biedenbach","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"e01433-20","DOI":"10.1128\/AAC.01433-20","article-title":"Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide","volume":"64","author":"Sader","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"e00297-20","DOI":"10.1128\/AAC.00297-20","article-title":"Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_302","doi-asserted-by":"crossref","unstructured":"Sader, H.S., Mendes, R.E., Ryan Arends, S.J., Doyle, T.B., and Castanheira, M. (2025). Activity of Aztreonam-avibactam and other \u03b2-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020\u20132022). BMC Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03500-8"},{"key":"ref_303","unstructured":"United States Food and Drug Administration (2026, March 19). EMBLAVEO (Aztreonam and Avibactam) for Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217906Orig1s000lbl.pdf."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-025-02258-x","article-title":"Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms","volume":"86","author":"Shirley","year":"2026","journal-title":"Drugs"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/jac\/dkab346","article-title":"Selection and characterization of mutational resistance to aztreonam\/avibactam in \u03b2-lactamase-producing Enterobacterales","volume":"77","author":"Mushtaq","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_306","doi-asserted-by":"crossref","unstructured":"Yu, W., Shen, P., Chen, Y., Zhou, K., Chi, X., and Xiao, Y. (2022). Epidemiology and Genomic Characteristics of Bloodstream Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae With Decreased Susceptibility to Aztreonam\/Avibactam in China. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.926209"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1093\/jac\/dkab279","article-title":"Investigation of mechanisms responsible for decreased susceptibility of aztreonam\/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019","volume":"76","author":"Mendes","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkaa021","article-title":"High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam\/avibactam","volume":"75","author":"Periasamy","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/jac\/dku568","article-title":"Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam\/avibactam: Role of a novel insertion in PBP3","volume":"70","author":"Alm","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"e00389-17","DOI":"10.1128\/AAC.00389-17","article-title":"Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam","volume":"61","author":"Zhang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"dlae141","DOI":"10.1093\/jacamr\/dlae141","article-title":"Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline","volume":"6","author":"Haidar","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"107256","DOI":"10.1016\/j.ijantimicag.2024.107256","article-title":"Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeability","volume":"64","author":"Tellapragada","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Ma, K., and Zong, Z. (2022). Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in Escherichia coli. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1047109"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"e00821-20","DOI":"10.1128\/mSystems.00821-20","article-title":"Struggle To Survive: The Choir of Target Alteration, Hydrolyzing Enzyme, and Plasmid Expression as a Novel Aztreonam-Avibactam Resistance Mechanism","volume":"5","author":"Ma","year":"2020","journal-title":"mSystems"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"e0023624","DOI":"10.1128\/aac.00236-24","article-title":"Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection","volume":"68","author":"Moeck","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1093\/jac\/dkv239","article-title":"Activity of OP0595\/\u03b2-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing \u03b2-lactamases","volume":"70","author":"Livermore","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_317","unstructured":"ClinicalTrials.gov [Internet] (2026, April 09). Bethesda (MD): National Library of Medicine (US). Identifier NCT04979806, Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) [Updated 30 September 2025], Available online: https:\/\/clinicaltrials.gov\/study\/NCT04979806?term=cefepime-zidebactam&rank=5."},{"key":"ref_318","unstructured":"ClinicalTrials.gov [Internet] (2026, April 09). Bethesda (MD): National Library of Medicine (US). Identifier NCT05887908, Efficacy and Safety of Cefepime\/Nacubactam or Aztreonam\/Nacubactam Compared to Imipenem\/Cilastatin in Subjects with Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis (Integral-1) [Updated 24 December 2025], Available online: https:\/\/clinicaltrials.gov\/study\/NCT05887908?term=cefepime-nacubactam&rank=1#study-overview."},{"key":"ref_319","unstructured":"ClinicalTrials.gov [Internet] (2026, April 09). Bethesda (MD): National Library of Medicine (US). Identifier NCT05905055, P3 Study to Assess Efficacy and Safety of Cefepime\/Nacubactam and Aztreonam\/Nacubactam Versus Best Available Therapy for Adults with Infection Due to Carbapenem Resistant Enterobacterales (Integral-2) [Updated 8 April 2026], Available online: https:\/\/clinicaltrials.gov\/study\/NCT05905055?term=cefepime-nacubactam&rank=2."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/4\/413\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:17:18Z","timestamp":1777353438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/4\/413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":320,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["antibiotics15040413"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15040413","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]}}}